Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $30.9950 (1.99%) ($30.7500 - $31.6670) on Fri. Oct. 9, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.79% (three month average) | RSI | 72 | Latest Price | $30.9950(1.99%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 9.6% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -1.895% in a week (0% probabilities). VIXM(-37%) VXX(-33%) UUP(-18%) DRIV(-6%) TBT(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.895% (StdDev 3.79%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $29.64(4.57%) | 10 Day Moving Average | $28.1(10.3%) | 20 Day Moving Average | $26.67(16.22%) | To recent high | 0% | To recent low | 67.7% | Market Cap | $3.925b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |